David O’Connell, director of Scientific Affairs at PCI Pharma Services, Tredegar site, shares insight on how CDMOs, like PCI, can provide end-to-end solutions in the growing demand of high potency manufacturing.
David O’Connell, director of Scientific Affairs at PCI Pharma Services looks at the ways in which pharmaceutical manufacturers can overcome challenges in potent compound granulation.
David O’Connell, director of scientific affairs at PCI Pharma Services, discusses the principles of roller compaction – particularly in the development and manufacturing of solid oral dosage forms containing highly potent active pharmaceutical ingred
David O’Connell, director Pharmaceutical Development at PCI Pharma Services discusses the advantages of dry granulation as an alternative to traditional wet granulation for the development and manufacturing of solid oral dosage forms…
